Rafael Pharmaceuticals Inc. (“Rafael” or the “Company”), announced its partner Ono Pharmaceutical Co., Ltd. (“Ono”), has begun a Phase 1 study in Japan for patients with pancreatic cancer. The multicenter, open-label study is evaluating the efficacy and safety of Rafael’s lead compound, CPI-613® (devimistat), labeled as ONO-7912 in Japan, in combination with modified FOLFIRINOX (mFFX) in patients with pancreatic cancer refractory or intolerance to chemotherapy including gemcitabine. This announcement comes on the heels of Rafael reaching its target enrollment of 500 patients in its global Phase 3 trial.